Eli Lilly preps big solanezumab study for Alzheimer's; Report: 30 GSK China staffers under house arrest: Blog: Phase I trials dwindling fast;

 @FierceBiotech: ICYMI yesterday: The 2013 biotech IPO scene turns red hot. Special report | Follow @FierceBiotech

 @JohnCFierce: Afatinib OK'd for lung cancer. To be sold as Gilotrif? Sounds like a character in Lord of the Rings. FDA release | Follow @JohnCFierce

 @RyanMFierce: Mitsubishi to snap up vaccine developer Medicago in $357M deal. News | Follow @RyanMFierce

 @EmilyMFierce: In case you missed it yesterday: Senate committee approves funding increase for NIH in FY 2014. Article | Follow @EmilyMFierce

> Eli Lilly ($LLY) investigators today reviewed their upcoming trial on the Alzheimer's drug solanezumab. This is the drug giant's third shot at a successful Phase III. Two earlier attempts ended in failure. But Lilly says it learned a lot from those setbacks and will recruit more patients and employ better screening technology to identify mid-stage patients able to respond to the treatment, which is designed to remove toxic levels of amyloid beta from the brain. The drug study won't be over anytime soon, though. Lilly expects that the recruitment for this trial will take 22 months and plans to treat patients for 18 months. It is keeping an option on reporting interim results but won't decide on that until well into the study. Report

> The Telegraph reports that 30 GlaxoSmithKline ($GSK) staffers are being held under house arrest, including 5 or 6 executives, as Chinese officials probe allegations of widespread corruption and bribery. Report

Medical Device News

 @FierceMedDev: Arch, a wound care device startup, raises $7.3M. Item | Follow @FierceMedDev

 @MarkHFierce: So, which med tech companies are facing FDA warning letters this week? Roundup | Follow @MarkHFierce

 @DamianFierce: Edwards prevailed in the latest round of its heart valve patent dispute with Medtronic. Report | Follow @DamianFierce

> PIP breast implant scandal a boon to U.K. company. Report

> Boston Scientific launches catheter as patent suit pends. Story

> Health insurance cost-cutting climate hampers new devices. Article

Pharma News

 @FiercePharma: CEO Joe Jimenez figures Novartis can grow "slightly faster than the market" in China: Report | Follow @FiercePharma

 @EricPFierce: BMS, Pfizer say FDA to review Eliquis for new use. Yesterday's story | Follow @EricPFierce

 @CarlyHFierce: Vivus urges shareholders to vote as meeting nears; First Manhattan trying to instate 9 board members. ICYMI yesterday | Follow @CarlyHFierce

> FDA approval for Boehringer means fast competition to Roche's targeted Tarceva. Article

> Sanofi starts producing dengue vax in effort to keep lead in lucrative space. Report

> Telegraph: Sources say 30 GSK employees under house arrest. Story

Blog Watch: John LaMattina considers the impact of a dwindling number of Phase I trials at some top companies. "Assuming that this weaker phase 1/2 pipeline is being experienced across the industry, then the current record rate of FDA new drug approvals could peter out by the end of this decade." Column

Suggested Articles

It’s been a minute, but AstraZeneca has gotten the FDA’s all-clear to restart the U.S. study of its COVID-19 vaccine.

Combining KSQ's USP1 inhibitor with Merck and AstraZeneca's PARP inhibitor Lynparza was more effective in animal models than either drug on its own.

Solid Bio is teaming up with Ultragenyx on Duchenne muscular dystrophy in a deal worth $40 million upfront but could net it another $255 million.